Compare SONM & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SONM | KZIA |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 161.5M |
| IPO Year | 2019 | 1999 |
| Metric | SONM | KZIA |
|---|---|---|
| Price | $3.30 | $7.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 43.7K | ★ 241.3K |
| Earning Date | 10-31-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $59,109,000.00 | $1,199,108.00 |
| Revenue This Year | $127.68 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.17 | N/A |
| 52 Week Low | $3.21 | $2.86 |
| 52 Week High | $114.84 | $17.40 |
| Indicator | SONM | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 27.93 | 40.88 |
| Support Level | $4.93 | $6.65 |
| Resistance Level | $6.10 | $11.06 |
| Average True Range (ATR) | 0.57 | 2.03 |
| MACD | -0.21 | -0.62 |
| Stochastic Oscillator | 2.33 | 9.77 |
Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the Canada, and to Bell, Rogers, and Telus and Rogers, Telstra in Australia. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.